Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication.
Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.
We are currently advancing three ADC assets:
TUB-010 | Lymphoma, pre-IND; ready for partnering
TUB-030 | solid cancer, discovery
TUB-040 | solid cancer, discovery
Strong technology portfolio
Tub-tag and P5 by Tubulis - one company, two unique, complementing ADC conjugation technologies fulfilling the needs of 3rd generation ADCs: